Improved mPFS, ORR and mDoR in patients with Non-squamous NSCLC and PD-L1 scores ≥1%¹

Key Efficacy Outcome: mPFS

Etapidi with chemotherapy significantly prolonged median progression free survival by 29%

PFS benefits with Etapidi plus chemotherapy were consistent across most patient subgroups.

Independent review committee-assessed progression-free survival by prespecified subgroup in the ITT population

Key Efficacy Outcome: ORR & mDOR

Greater ORR and longer DoR with Etapidi plus chemotherapy versus chemotherapy alone

NSCLC, non small cell lung cancer; HR, hazard ratio; mDoR, median duration of response; mPFS, median progression-free survival; ORR; PD-L1, programmed death ligand 1.

Reference: : 1. Lu S, et al. J Thorac Oncol. 2021;16(9):1512-1522. 2. Lu S et al., ESMO OPEN 2024 volume 9, issue 10, https://doi.org/10.1016/j.esmoop.2024.103728

Improved mPFS, ORR and mDoR in patients with Non-squamous NSCLC and PD-L1 scores ≥1%1

Key Efficacy Outcome: mPFS

PFS benefits with Etapidi plus chemotherapy were consistent across most patient subgroups.

Key Efficacy Outcome: ORR & mDOR

Improved mPFS, ORR and mDoR in patients with Non-squamous NSCLC and PD-L1 scores ≥1%¹